HOME >> BIOLOGY >> NEWS
Brandeis and Brigham and Women's Hospital license technology for Gaucher's to Amicus Therapeutics

Waltham, MABrandeis University and Brigham and Women's Hospital today agreed to grant a license option to Amicus Therapeutics for a jointly-developed novel pharmaceutical technology that could be instrumental in finding new treatments for Gaucher Disease. Biochemists Raquel Lieberman, Gregory Petsko and Dagmar Ringe, each affiliated with both Brandeis and Brigham and Women's, invented a patentable technology related to the structure of acid beta-glucosidase, also known as GCase, and methods for identifying therapeutic agents. In collaboration with scientists at Amicus Therapeutics, the inventors discovered that GCase, the protein that is mutated in Gaucher Disease, undergoes a structural change near its active site upon binding to a small molecule that is in clinical trials for the treatment of the disease.

One emerging type of treatment for genetic diseases such as Gaucher Disease involves the use of small molecules known as pharmacological chaperones, which are proposed to help mutated, less stable proteins perform their normal function in the cells of patients with the disease. The identification of appropriate pharmacological chaperones and understanding how they work in the body are aided by knowing the structure of the target protein under different conditions and when bound to the small molecule.

Cranbury, New Jersey-based Amicus Therapeutics, which specializes in the discovery and development of pharmacological chaperones, will use this structure of GCase to look for additional small molecules that can keep the protein properly folded and stabilized.

"This work helps explain the way pharmacological chaperones work to stabilize proteins that are rendered less stable by genetic mutations in diseases such as Gaucher, Anderson-Fabry, and other genetic disorders," explained Petsko, the Gyula and Katica Tauber Professor of Biochemistry and Chemistry, Brandeis University and Adjunct Professor, Department of Neurology and Center
'"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
22-Feb-2007


Page: 1 2

Related biology news :

1. New Brandeis research sheds light on memory by erasing it
2. National Academy of Sciences elects 2 Brandeis University scientists to membership
3. Biogen Idec acquires Brandeis spin-out
4. HHMI awards Brandeis professor $1 million to draw minorities into science
5. Carl and Ruth Shapiro family donates $25 million for new science center at Brandeis University
6. American Physical Society honors outstanding achievements of two Brandeis scientists
7. Brandeis biologist wins top award in neuroscience
8. Brandeis wins $1 million grant to train scientists in solving 21-century biomedical problems
9. AAAS and Brandeis University announce 2005 Fellows
10. Brandeis leads collaborative team in researching chemical processes in brain
11. MIT, Brigham: Nanoparticles armed to combat cancer

Post Your Comments:
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... is pleased to announce the promotion of Yaniv ... of Digital Forensics. In Schiff,s new role as Director, ... team of digital forensics examiners and provide leadership within ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 Schiff ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
(Date:12/13/2014)... 2014  Vaccinex Inc., a clinical-stage biotechnology ... of therapeutic monoclonal antibodies to treat cancer ... a manuscript entitled "SEMA4D compromises blood–brain barrier, ... disease" in the January 2015 issue of ... highlights an important role for antibodies that ...
(Date:12/12/2014)... Switzerland (PRWEB) December 11, 2014 InSphero ... toxicity and efficacy testing, announced today that data presented ... 3D liver microtissues as a more predictive model system ... presented at the 2nd Annual Functional Analysis and ... to assess the response of InSphero’s 3D InSight™ ...
(Date:12/12/2014)... December 11, 2014 Pittcon is ... that includes over 2,000 technical presentations offered ... This year’s program covers a wide range ... biotechnology, biomedical, drug discovery, environmental, food science, fuels/energy, ... and water/wastewater. The Technical Program begins on ...
(Date:12/12/2014)... Philadelphia, PA (PRWEB) December 11, 2014 ... the newest members of the entrepreneurial community at the ... LLC. has a desk in the Bullpen coworking space ... cubical at 3711 Market Street. Oncoceutics is occupying an ... Technology Advancement at 3624 Market Street. , Denovo Health, ...
Breaking Biology Technology:Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3New Residents of Science Center’s Port Incubator Focus on Health IT and Cancer Treatment 2New Residents of Science Center’s Port Incubator Focus on Health IT and Cancer Treatment 3
Cached News: